Literature DB >> 6110503

Immediate cardiovascular responses to oral prazosin--effects of concurrent beta-blockers.

H L Elliott, K McLean, D J Sumner, P A Meredith, J L Reid.   

Abstract

Initiation of prazosin therapy may be complicated by the first-dose response of acute postural hypotension and tachycardia. The effects of beta-blocker on the responses to oral prazosin were studied in eight normotensive men. After 1 mg oral prazosin there was a marked postural fall in blood pressure to a lowest mean standing systolic pressure of 88 +/- 7 mm Hg (mean +/- SD), associated with a tachycardia of 117 +/- 13 bpm, and an increase in mean plasma norepinephrine concentration to 9.6 +/- 7.9 nmole/l. There was a linear relationship (r = 0.93) between plasma prazosin concentration and hypotensive effect. Concurrent propranolol 80 mg or primidolol 100 mg (a cardioselective beta-blocker) increased the severity and duration of the postural hypotensive response, with lowest mean systolic blood pressure (BP) of 79 +/- 7 and 75 +/- 9 mm Hg. There was no effect on the orthostatic release of norepinephrine but there was attenuation of the postural tachycardia. Concurrent beta-adrenergic blocking therapy, selective or nonselective, intensifies the immediate postural hypotensive response to the initial dose of prazosin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6110503     DOI: 10.1038/clpt.1981.40

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  26 in total

1.  Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: II. Duration of action, pharmacokinetics and concentration-effect relationships in normotensive subjects.

Authors:  R F Schafers; H L Elliott; P A Meredith; S H Miller; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

Review 2.  beta-blockers. Drug interactions of clinical significance.

Authors:  I Blaufarb; T M Pfeifer; W H Frishman
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

Review 3.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

4.  Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin.

Authors:  M S Lennard; J C McGourty; J H Silas
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

Review 5.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 6.  Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

Review 7.  Potentially significant drug interactions of class III antiarrhythmic drugs.

Authors:  Weeranuj Yamreudeewong; Michael DeBisschop; Linda G Martin; Dennis L Lower
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

8.  Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.

Authors:  J W Ward; A McBurney; P R Farrow; P Sharp
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects.

Authors:  H L Elliott; P A Meredith; D J Sumner; K McLean; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

Review 10.  Influence of drug formulation on drug concentration-effect relationships.

Authors:  G Castañeda-Hernández; G Caillé; P du Souich
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.